Understanding the two faces of the COVID-19 immune response to predict clinical course and define strategies for early and late phase intervention
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.043E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$549,034.11Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
Dr. S NierkensResearch Location
NetherlandsLead Research Institution
University Medical Center UtrechtResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Project description The immune system plays a striking double role in COVID-19. An effective immune response ensures that the virus is attacked and cleared away, but if that does not work properly, a hyper-activation of the immune system appears to arise, which can lead to serious problems. It is unclear what exactly goes wrong in the immune system in patients with a severe course and how they can best be treated. The use of immunosuppressive medications is one of the possible strategies. Research and expected outcomes In this study, a collaboration of the UMCU, RIVM and VUmc, a model of the underlying immune response in different phases of COVID is developed by measuring functional cellular defense and circulating protein profiles of patients of different ages and with a variation in disease severity. -19. In addition, predictive biomarkers will be identified and validated that provide insight into optimal timing for specific treatments.